Tessella Biosciences
Develops and commercializes ready-to-use, high-printability bioinks for extrusion-based 3D bioprinting, enabling researchers to create realistic tissue models like lung tissue that expand and contract at body temperature.
- CEO / Founder
- Jose Moran-Mirabal
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $395K
- Latest Round
- Seed
- Key Investors
- McMaster Seed Fund; Ontario Genomics
Technology & Products
Key Products
Bioinks for extrusion 3D bioprinting; Tunable biomaterial inks for tissue modeling
Technological Advantage
Proprietary bioink formulations achieve high printability and stability at physiological temperatures, protected by university research and potential patents (specific patents not publicly listed). Advantage is replicable but defended through ongoing R&D and first-mover expertise in temperature-stable bioinks.
Differentiation
Value Proposition
Reduces bioprinting setup time from days to under 1 hour with plug-and-play bioinks that require minimal training, while enabling printing of stable, complex tissue structures at 37°C (body temperature) versus conventional bioinks that require low temperatures and often collapse.
How They Differentiate
3x faster setup than conventional bioink preparation (under 1 hour vs. days) with temperature-stable printing at 37°C vs. competitors' low-temperature requirements that risk structural collapse; focused on ready-to-use formulations versus custom mixing approaches.
Market & Competition
Target Customers
Academic and industrial researchers in biomedical research, regenerative medicine, and tissue engineering
Industry Verticals
Medical; Biotechnology; Research & Development
Competitors
BICO (formerly CELLINK); Clecell, Inc.
Growth & Milestones
Growth Metrics
Secured $245,000 seed funding to expand operations and product portfolio; first customers reported with positive feedback.
Major Milestones
Developed bioink for 3D printing realistic, expandable lung tissue; Secured $245,000 from McMaster Seed Fund; Received $150,000 non-dilutive funding from Ontario Genomics BioCreate program